{"name":"Memorial Sloan Kettering Cancer Center","slug":"memorial-sloan-kettering-cancer-center","ticker":"","exchange":"","domain":"mskcc.org","description":"","hq":"New York City","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":21,"colorKey":"oncology","drugs":[{"name":"Drug Eluting Bead Transarterial Chemoembolization","genericName":"Drug Eluting Bead Transarterial Chemoembolization","slug":"drug-eluting-bead-transarterial-chemoembolization","indication":"Other","status":"phase_1"},{"name":"HIPEC with Mitomycin-C","genericName":"HIPEC with Mitomycin-C","slug":"hipec-with-mitomycin-c","indication":"Other","status":"phase_2"},{"name":"Infusion of MCARH109 T cells","genericName":"Infusion of MCARH109 T cells","slug":"infusion-of-mcarh109-t-cells","indication":"Other","status":"phase_1"},{"name":"PECS-1","genericName":"PECS-1","slug":"pecs-1","indication":"Other","status":"marketed"},{"name":"131I-MIP-1095","genericName":"131I-MIP-1095","slug":"131i-mip-1095","indication":"Other","status":"phase_1"},{"name":"Atezolizumb","genericName":"Atezolizumb","slug":"atezolizumb","indication":"Other","status":"phase_1"},{"name":"Embospheres","genericName":"Embospheres","slug":"embospheres","indication":"Other","status":"phase_1"},{"name":"HER2 directed therapy","genericName":"HER2 directed therapy","slug":"her2-directed-therapy","indication":"Other","status":"phase_1"},{"name":"M28z1XXPD1DNR CAR","genericName":"M28z1XXPD1DNR CAR","slug":"m28z1xxpd1dnr-car","indication":"Other","status":"phase_1"},{"name":"MUC-2-KLH vaccine","genericName":"MUC-2-KLH vaccine","slug":"muc-2-klh-vaccine","indication":"Other","status":"phase_1"},{"name":"Maitake","genericName":"Maitake","slug":"maitake","indication":"Other","status":"marketed"},{"name":"PVB Protocol","genericName":"PVB Protocol","slug":"pvb-protocol","indication":"Other","status":"marketed"},{"name":"Propofol+ Rocuronium+ Fentanyl + Inhalational","genericName":"Propofol+ Rocuronium+ Fentanyl + Inhalational","slug":"propofol-rocuronium-fentanyl-inhalational","indication":"Induction and maintenance of general anesthesia for surgical procedures","status":"phase_3"},{"name":"Revaree Plus","genericName":"Revaree Plus","slug":"revaree-plus","indication":"Other","status":"marketed"},{"name":"Trametinib 1.5 MG","genericName":"Trametinib 1.5 MG","slug":"trametinib-1-5-mg","indication":"Other","status":"phase_1"},{"name":"Xevinapan","genericName":"Xevinapan","slug":"xevinapan","indication":"Other","status":"phase_2"},{"name":"cisplatin or carboplatin-based","genericName":"cisplatin or carboplatin-based","slug":"cisplatin-or-carboplatin-based","indication":"Other","status":"phase_1"},{"name":"concurrent capecitabine or 5-FU","genericName":"concurrent capecitabine or 5-FU","slug":"concurrent-capecitabine-or-5-fu","indication":"Other","status":"phase_1"},{"name":"oral β-glucan","genericName":"oral β-glucan","slug":"oral-glucan","indication":"Other","status":"phase_1"},{"name":"pilimumab","genericName":"pilimumab","slug":"pilimumab","indication":"Other","status":"phase_2"},{"name":"recombinant 70-kD heat-shock protein","genericName":"recombinant 70-kD heat-shock protein","slug":"recombinant-70-kd-heat-shock-protein","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":19,"colorKey":"immunology","drugs":[{"name":"Systemic Therapy/Standard of Care","genericName":"Systemic Therapy/Standard of Care","slug":"systemic-therapy-standard-of-care","indication":"Metastatic non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"placebo tablets and questionaires","genericName":"placebo tablets and questionaires","slug":"placebo-tablets-and-questionaires","indication":"Assessment of patient-reported outcomes in cancer patients","status":"phase_3"},{"name":"therapeutic testosterone","genericName":"therapeutic testosterone","slug":"therapeutic-testosterone","indication":"Testosterone deficiency (hypogonadism)","status":"marketed"},{"name":"Azacitidine (AZA)","genericName":"Azacitidine (AZA)","slug":"azacitidine-aza","indication":"Myelodysplastic syndromes (MDS)","status":"marketed"},{"name":"Bacillus Calmette-Guérin (BCG)","genericName":"Bacillus Calmette-Guérin (BCG)","slug":"bacillus-calmette-gu-rin-bcg","indication":"Non-muscle-invasive bladder cancer (NMIBC), including carcinoma in situ","status":"phase_3"},{"name":"CAR T cells","genericName":"CAR T cells","slug":"car-t-cells","indication":"B-cell acute lymphoblastic leukemia (ALL)","status":"phase_3"},{"name":"Daratumumab Hyaluronidase-fihj","genericName":"Daratumumab Hyaluronidase-fihj","slug":"daratumumab-hyaluronidase-fihj","indication":"Multiple myeloma (newly diagnosed and relapsed/refractory)","status":"marketed"},{"name":"Empirical Vancomycin","genericName":"Empirical Vancomycin","slug":"empirical-vancomycin","indication":"Empirical treatment of suspected or confirmed gram-positive infections in immunocompromised cancer patients","status":"phase_3"},{"name":"GnRH agonist/antagonist","genericName":"GnRH agonist/antagonist","slug":"gnrh-agonist-antagonist","indication":"Prostate cancer (hormone-sensitive)","status":"marketed"},{"name":"Hemostatic Agent","genericName":"Hemostatic Agent","slug":"hemostatic-agent","indication":"Perioperative bleeding control","status":"phase_3"},{"name":"LAR Lanreotide","genericName":"LAR Lanreotide","slug":"lar-lanreotide","indication":"Acromegaly","status":"marketed"},{"name":"Mitomycin C (MMC)","genericName":"Mitomycin C (MMC)","slug":"mitomycin-c-mmc","indication":"Gastric cancer","status":"phase_3"},{"name":"Oxaliplatin (OXAL)","genericName":"Oxaliplatin (OXAL)","slug":"oxaliplatin-oxal","indication":"Metastatic colorectal cancer (in combination with 5-FU/leucovorin)","status":"marketed"},{"name":"Pembrolizuma","genericName":"Pembrolizuma","slug":"pembrolizuma","indication":"Advanced or recurrent cervical cancer","status":"marketed"},{"name":"Pembrolizumab (MK-3475)","genericName":"Pembrolizumab (MK-3475)","slug":"pembrolizumab-mk-3475","indication":"Metastatic melanoma","status":"phase_3"},{"name":"Prophylactic Vancomycin","genericName":"Prophylactic Vancomycin","slug":"prophylactic-vancomycin","indication":"Prophylaxis of bacterial infections in immunocompromised cancer patients undergoing chemotherapy","status":"phase_3"},{"name":"Trastuzumab deruxtecan-nxki","genericName":"Trastuzumab deruxtecan-nxki","slug":"trastuzumab-deruxtecan-nxki","indication":"HER2-positive metastatic breast cancer","status":"marketed"},{"name":"Vancomycin and Gentamicin","genericName":"Vancomycin and Gentamicin","slug":"vancomycin-and-gentamicin","indication":"Empiric treatment of febrile neutropenia in cancer patients","status":"marketed"},{"name":"peripheral blood stem cell transplantation","genericName":"peripheral blood stem cell transplantation","slug":"peripheral-blood-stem-cell-transplantation","indication":"Treatment of various blood cancers, including leukemia and lymphoma","status":"phase_3"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"infectious","drugs":[{"name":"Serratus","genericName":"Serratus","slug":"serratus","indication":"Dermatology","status":"marketed"},{"name":"Topical Dapsone 5% Gel","genericName":"Topical Dapsone 5% Gel","slug":"topical-dapsone-5-gel","indication":"Acne vulgaris","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"DANYELZA","genericName":"DANYELZA","slug":"danyelza","indication":"Relapsed or refractory high-risk neuroblastoma (in combination with GM-CSF)","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Meclofenamate","genericName":"Meclofenamate","slug":"meclofenamate","indication":"Dysmenorrhea","status":"marketed"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"anti-thymocyte globulin (ATG)","genericName":"anti-thymocyte globulin (ATG)","slug":"anti-thymocyte-globulin-atg","indication":"Prevention of organ rejection in kidney transplant patients","status":"phase_3"}]}],"pipeline":[{"name":"Drug Eluting Bead Transarterial Chemoembolization","genericName":"Drug Eluting Bead Transarterial Chemoembolization","slug":"drug-eluting-bead-transarterial-chemoembolization","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HIPEC with Mitomycin-C","genericName":"HIPEC with Mitomycin-C","slug":"hipec-with-mitomycin-c","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Infusion of MCARH109 T cells","genericName":"Infusion of MCARH109 T cells","slug":"infusion-of-mcarh109-t-cells","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"PECS-1","genericName":"PECS-1","slug":"pecs-1","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Systemic Therapy/Standard of Care","genericName":"Systemic Therapy/Standard of Care","slug":"systemic-therapy-standard-of-care","phase":"phase_3","mechanism":"This drug targets the PD-1 receptor to inhibit cancer cell growth.","indications":["Metastatic non-small cell lung cancer, PD-L1 positive","Metastatic melanoma","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"placebo tablets and questionaires","genericName":"placebo tablets and questionaires","slug":"placebo-tablets-and-questionaires","phase":"phase_3","mechanism":"This drug is a placebo, having no active pharmacological mechanism.","indications":["Assessment of patient-reported outcomes in cancer patients"],"catalyst":""},{"name":"therapeutic testosterone","genericName":"therapeutic testosterone","slug":"therapeutic-testosterone","phase":"marketed","mechanism":"Therapeutic testosterone replaces or supplements endogenous testosterone to restore normal hormonal levels and physiological function.","indications":["Testosterone deficiency (hypogonadism)","Potential supportive care in cancer patients with low testosterone"],"catalyst":""},{"name":"131I-MIP-1095","genericName":"131I-MIP-1095","slug":"131i-mip-1095","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Atezolizumb","genericName":"Atezolizumb","slug":"atezolizumb","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Azacitidine (AZA)","genericName":"Azacitidine (AZA)","slug":"azacitidine-aza","phase":"marketed","mechanism":"Azacitidine inhibits DNA methyltransferase, leading to DNA demethylation and reactivation of silenced tumor suppressor genes.","indications":["Myelodysplastic syndromes (MDS)","Acute myeloid leukemia (AML)","Chronic myelomonocytic leukemia (CMML)"],"catalyst":""},{"name":"Bacillus Calmette-Guérin (BCG)","genericName":"Bacillus Calmette-Guérin (BCG)","slug":"bacillus-calmette-gu-rin-bcg","phase":"phase_3","mechanism":"BCG is a live attenuated mycobacterial vaccine that stimulates the immune system to recognize and destroy cancer cells, particularly in the bladder.","indications":["Non-muscle-invasive bladder cancer (NMIBC), including carcinoma in situ","High-grade urothelial carcinoma of the bladder"],"catalyst":""},{"name":"CAR T cells","genericName":"CAR T cells","slug":"car-t-cells","phase":"phase_3","mechanism":"CAR T cells are engineered immune cells that recognize and kill cancer cells by expressing chimeric antigen receptors targeting tumor-associated antigens.","indications":["B-cell acute lymphoblastic leukemia (ALL)","Diffuse large B-cell lymphoma (DLBCL)","Multiple myeloma","Other hematologic and solid malignancies (investigational)"],"catalyst":""},{"name":"DANYELZA","genericName":"DANYELZA","slug":"danyelza","phase":"marketed","mechanism":"DANYELZA is a monoclonal antibody that targets GD2, a glycolipid antigen expressed on neuroblastoma cells, enabling immune-mediated tumor cell destruction.","indications":["Relapsed or refractory high-risk neuroblastoma (in combination with GM-CSF)"],"catalyst":""},{"name":"Daratumumab Hyaluronidase-fihj","genericName":"Daratumumab Hyaluronidase-fihj","slug":"daratumumab-hyaluronidase-fihj","phase":"marketed","mechanism":"Daratumumab binds to CD38 on multiple myeloma cells to trigger their destruction, while hyaluronidase enables faster subcutaneous administration by breaking down hyaluronic acid in tissue.","indications":["Multiple myeloma (newly diagnosed and relapsed/refractory)","Light chain myeloma"],"catalyst":""},{"name":"Embospheres","genericName":"Embospheres","slug":"embospheres","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Empirical Vancomycin","genericName":"Empirical Vancomycin","slug":"empirical-vancomycin","phase":"phase_3","mechanism":"Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.","indications":["Empirical treatment of suspected or confirmed gram-positive infections in immunocompromised cancer patients","MRSA infections in cancer patients"],"catalyst":""},{"name":"GnRH agonist/antagonist","genericName":"GnRH agonist/antagonist","slug":"gnrh-agonist-antagonist","phase":"marketed","mechanism":"GnRH agonists/antagonists suppress gonadotropin-releasing hormone signaling to reduce sex hormone production, used in oncology to manage hormone-sensitive cancers and their treatment side effects.","indications":["Prostate cancer (hormone-sensitive)","Breast cancer (hormone-sensitive)","Cancer treatment-related hot flashes and sexual dysfunction"],"catalyst":""},{"name":"HER2 directed therapy","genericName":"HER2 directed therapy","slug":"her2-directed-therapy","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Hemostatic Agent","genericName":"Hemostatic Agent","slug":"hemostatic-agent","phase":"phase_3","mechanism":"A hemostatic agent promotes blood clotting and stops bleeding by enhancing coagulation cascade activation or platelet function.","indications":["Perioperative bleeding control","Hemorrhage management in cancer surgery"],"catalyst":""},{"name":"LAR Lanreotide","genericName":"LAR Lanreotide","slug":"lar-lanreotide","phase":"marketed","mechanism":"Lanreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone and other hormones.","indications":["Acromegaly","Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)","Carcinoid syndrome"],"catalyst":""},{"name":"M28z1XXPD1DNR CAR","genericName":"M28z1XXPD1DNR CAR","slug":"m28z1xxpd1dnr-car","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"MUC-2-KLH vaccine","genericName":"MUC-2-KLH vaccine","slug":"muc-2-klh-vaccine","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Maitake","genericName":"Maitake","slug":"maitake","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Meclofenamate","genericName":"Meclofenamate","slug":"meclofenamate","phase":"marketed","mechanism":"Aldo-keto reductase family 1 member C1, Aldo-keto reductase family 1 member C2, Aldo-keto reductase family 1 member C3","indications":["Dysmenorrhea","Menorrhagia","Osteoarthritis","Pain","Rheumatoid arthritis"],"catalyst":""},{"name":"Mitomycin C (MMC)","genericName":"Mitomycin C (MMC)","slug":"mitomycin-c-mmc","phase":"phase_3","mechanism":"Mitomycin C is an alkylating agent that cross-links DNA strands, preventing cell division and triggering cancer cell death.","indications":["Gastric cancer","Pancreatic cancer","Colorectal cancer","Bladder cancer (intravesical)"],"catalyst":""},{"name":"Oxaliplatin (OXAL)","genericName":"Oxaliplatin (OXAL)","slug":"oxaliplatin-oxal","phase":"marketed","mechanism":"Oxaliplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill rapidly dividing cancer cells.","indications":["Metastatic colorectal cancer (in combination with 5-FU/leucovorin)","Adjuvant treatment of stage III colon cancer (in combination with 5-FU/leucovorin)","Advanced gastric cancer","Non-small cell lung cancer (in combination regimens)"],"catalyst":""},{"name":"PVB Protocol","genericName":"PVB Protocol","slug":"pvb-protocol","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Pembrolizuma","genericName":"Pembrolizuma","slug":"pembrolizuma","phase":"marketed","mechanism":"Programmed cell death protein 1","indications":["Advanced or recurrent cervical cancer","Classical Hodgkin lymphoma","Endometrial carcinoma progressing after chemotherapy","HER2-negative breast cancer","Malignant tumor of head and/or neck"],"catalyst":""},{"name":"Pembrolizumab (MK-3475)","genericName":"Pembrolizumab (MK-3475)","slug":"pembrolizumab-mk-3475","phase":"phase_3","mechanism":"Pembrolizumab is a monoclonal antibody that blocks PD-1 on T cells, allowing the immune system to recognize and attack cancer cells.","indications":["Metastatic melanoma","Non-small cell lung cancer (NSCLC)","Head and neck squamous cell carcinoma","Hodgkin lymphoma","Urothelial carcinoma"],"catalyst":""},{"name":"Prophylactic Vancomycin","genericName":"Prophylactic Vancomycin","slug":"prophylactic-vancomycin","phase":"phase_3","mechanism":"Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall disruption.","indications":["Prophylaxis of bacterial infections in immunocompromised cancer patients undergoing chemotherapy"],"catalyst":""},{"name":"Propofol+ Rocuronium+ Fentanyl + Inhalational","genericName":"Propofol+ Rocuronium+ Fentanyl + Inhalational","slug":"propofol-rocuronium-fentanyl-inhalational","phase":"phase_3","mechanism":"This is a combination anesthetic regimen that induces unconsciousness, provides muscle paralysis, and delivers pain relief for surgical procedures.","indications":["Induction and maintenance of general anesthesia for surgical procedures"],"catalyst":""},{"name":"Revaree Plus","genericName":"Revaree Plus","slug":"revaree-plus","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Serratus","genericName":"Serratus","slug":"serratus","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Topical Dapsone 5% Gel","genericName":"Topical Dapsone 5% Gel","slug":"topical-dapsone-5-gel","phase":"phase_3","mechanism":"Topical dapsone reduces inflammation and bacterial colonization in skin lesions through its antimicrobial and anti-inflammatory properties.","indications":["Acne vulgaris","Rosacea","Other inflammatory skin conditions"],"catalyst":""},{"name":"Trametinib 1.5 MG","genericName":"Trametinib 1.5 MG","slug":"trametinib-1-5-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Trastuzumab deruxtecan-nxki","genericName":"Trastuzumab deruxtecan-nxki","slug":"trastuzumab-deruxtecan-nxki","phase":"marketed","mechanism":"Trastuzumab deruxtecan-nxki is an antibody-drug conjugate that binds HER2-positive cancer cells and delivers a topoisomerase I inhibitor payload to kill them.","indications":["HER2-positive metastatic breast cancer","HER2-positive gastric or gastroesophageal junction adenocarcinoma","HER2-low metastatic breast cancer"],"catalyst":""},{"name":"Vancomycin and Gentamicin","genericName":"Vancomycin and Gentamicin","slug":"vancomycin-and-gentamicin","phase":"marketed","mechanism":"Vancomycin and gentamicin are a combination antibiotic regimen that inhibits bacterial cell wall synthesis and protein synthesis to treat serious infections.","indications":["Empiric treatment of febrile neutropenia in cancer patients","Serious gram-positive and gram-negative bacterial infections in immunocompromised hosts"],"catalyst":""},{"name":"Xevinapan","genericName":"Xevinapan","slug":"xevinapan","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"anti-thymocyte globulin (ATG)","genericName":"anti-thymocyte globulin (ATG)","slug":"anti-thymocyte-globulin-atg","phase":"phase_3","mechanism":"Anti-thymocyte globulin (ATG) works by binding to and depleting T-lymphocytes, which are a type of immune cell.","indications":["Prevention of organ rejection in kidney transplant patients","Treatment of aplastic anemia"],"catalyst":""},{"name":"cisplatin or carboplatin-based","genericName":"cisplatin or carboplatin-based","slug":"cisplatin-or-carboplatin-based","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"concurrent capecitabine or 5-FU","genericName":"concurrent capecitabine or 5-FU","slug":"concurrent-capecitabine-or-5-fu","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"oral β-glucan","genericName":"oral β-glucan","slug":"oral-glucan","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"peripheral blood stem cell transplantation","genericName":"peripheral blood stem cell transplantation","slug":"peripheral-blood-stem-cell-transplantation","phase":"phase_3","mechanism":"Peripheral blood stem cell transplantation involves the transfer of stem cells from the blood into the body to help the bone marrow recover after chemotherapy or radiation.","indications":["Treatment of various blood cancers, including leukemia and lymphoma"],"catalyst":""},{"name":"pilimumab","genericName":"pilimumab","slug":"pilimumab","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"recombinant 70-kD heat-shock protein","genericName":"recombinant 70-kD heat-shock protein","slug":"recombinant-70-kd-heat-shock-protein","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxQZko3RjJlaDBKVHdSM0h1U0FBRVctWW92V0RDN3Rfa3lPSWlXWjZaZFlfQ0ZXNjduSUZ5cEprdlVkckVOOUtEU09RdXVCUVJzQmhPdHU1NF91WmlfUjQ4ZVF5czVwVHRSa01VdENKanZPQTMzUERxaVpQMFZacDZrOXRFekNYLXR5NmJXc01OdEFvd2RHTHlod1IwdGpQMUZpbXJsRi13X2hwem1PbXI2ZEpsd3pGRGJTNHJmZkpIN0ZjWjJjUUg3SUs5ZHh5T2xLYzIyQVFnOG96T1dwWHZ1NmEyX0ZoZlU?oc=5","date":"2026-04-08","type":"pipeline","source":"BioPharma APAC","summary":"Lumonus And Memorial Sloan Kettering Cancer Center Collaborate To Scale Automated Radiation Therapy Planning - BioPharma APAC","headline":"Lumonus And Memorial Sloan Kettering Cancer Center Collaborate To Scale Automated Radiation Therapy Planning","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNRExDcllMV3VaQ0JndmtLMFRqc0dkNXRpRFk4NWZVcElEcUZyQmR6QmlUQXVkX1UyMmpRSUtDWElYdEE0djdLUThtcEJGak0tWUQ2aHgwN3l3ZDhOU2F3ZTJNVjh5UkdEZWN2cWo2NUVIeWFMTXdyWWVLdkktTlI2V0xkdXJ0T1FHVm11R1FqZHJkeWZlVk9NZEdfaTgxTm9RZ2xNNEpYVi1xOTFLWFZyQjJqV1hVVVNPZjMzSUI3N3A?oc=5","date":"2026-02-04","type":"pipeline","source":"Fierce Pharma","summary":"Editor's Pick: How Memorial Sloan Kettering Cancer Center Scaled EHR-to-EDC Technology - Fierce Pharma","headline":"Editor's Pick: How Memorial Sloan Kettering Cancer Center Scaled EHR-to-EDC Technology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxOM0ZFVEdZZEVKRnJaZk1ydVJGLURqbXlMZjhrZjBHUkxVa3dXajB1MXFxMldFb2NYVHh0eW9Yby15NkluSVBEVElEa1NOUVE2aDNoQ2tTQnRGSTZZUDlvWE8xblpsaF9WNjA1cTZzRzVjT05RWEQxektsTXNYZHFCYXd3d2pRN3l0QzhkTGo4SHY0VTFSM3VlUUxFYlctdTRzOW14bGtucnh5blAyb0F1QTZPS2M5R2dNZFBwQ1V6LUMwdml5OS1uTU1OZXB6alNsZ0RsRDRKdF9XNnlCQzZEdQ?oc=5","date":"2025-10-23","type":"pipeline","source":"News-Medical","summary":"GemPharmatech collaborates with MSK Cancer Center to accelerate discovery of therapeutic antibodies - News-Medical","headline":"GemPharmatech collaborates with MSK Cancer Center to accelerate discovery of therapeutic antibodies - News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE12Q3Z3T3Y5LVc5U1ROcmdPQ2tGQUxxQ1hoOEFEU1NLTkJRN3NYRkdfeUJTVlZjVnJvQWpmdzExTWpkUGRGQmp2cG5BR09BSkoyUXZ0OXZ3ZWxwSzhERGxTb29LUHEwUTBqS1g4eVE5UmNyUkU?oc=5","date":"2025-09-02","type":"pipeline","source":"Fierce Pharma","summary":"Andrea Cercek & Luis Diaz Jr. - Fierce Pharma","headline":"Andrea Cercek & Luis Diaz Jr.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPUEV4NG1FeGNJUXhaX19hRTR0STdBeEV6UHAyMGtjVlpXS0FVNjRUU3c0U0h6azZkMktDWTJzRWo5UUJ5ZnFpenhvdVpUMUVCZ01lUkxwVl9KUVgyZ2owclRPOUVxQ1hFT1Y4WjRzdHpSbjZJMnJud1U2c21IZy1ERXVqRU92YzdMVC1Pd29MajhUX09iMVIwOWpPZVFncU4zbm9RdHg2eVh3LXJ0ckVUOA?oc=5","date":"2025-06-20","type":"deal","source":"mskcc.org","summary":"MSK Expands Collaboration with Curadev Through MSK Therapeutics Accelerator Program - mskcc.org","headline":"MSK Expands Collaboration with Curadev Through MSK Therapeutics Accelerator Program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxPc2x6Z1lEY1NoSHFtWU56RmJPVUpaVWZHVkQwNmRGcVdOZXlLM2dGemIwN08tQjh4UHpFTW94bHZfQ2ZlQ2ZjOVRNRU5GYTcwSzY1YkRkc0hJbGdQY0xhZGlfelhGSFhqY0NsbTBKYi1SaDRXQ2tyREhEbUw1Nk1vOEdkNDR4MnE1X0Y0TFR3MzJVbnRGTWJjWHZYZm1UN3BnZE5TeWM2Rk9UUlNMSHd6ZG0zYjJoWlV6aWtHQWlxc2JHZThaR0ZwalEzVUUyM1pRRDZ3R013Xy0tQ0I5Z1VJUmZlY0hkM3BaaFc0?oc=5","date":"2025-06-10","type":"deal","source":"prnewswire.com","summary":"Curadev Expands Strategic Collaboration for CRD3874-SI Through MSK Therapeutics Accelerator Program - prnewswire.com","headline":"Curadev Expands Strategic Collaboration for CRD3874-SI Through MSK Therapeutics Accelerator Program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5PM1ZRenNwUXdpOW5FOWZqazVLMUg1NzRlVlVuZkFFOGhSMGZ3cTZQeE5OZ1dOOUNrUTdzZUZIQnNfMzFiOXBjMDJ1eHNLTXkyckpn?oc=5","date":"2025-04-28","type":"regulatory","source":"FirstWord Pharma","summary":"AACR25: Patients with dMMR cancers remain disease-free two years post-Jemperli - FirstWord Pharma","headline":"AACR25: Patients with dMMR cancers remain disease-free two years post-Jemperli","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOZVdad0dfMUlzNndhWkNoLUpXQ0UtY1dHWG5jN1VfUzhKaktpMHB6b0YwX2tZMjltTE53dl94dUNjVGZaNW5LUEJ2NkNVWlN5UWZ3MkpDN0R6d0ZPNmswb1VRN21DWUxkRXQyLWNiazNhdk5OY0U4UDBza1lFcm9OSGx4YWd1Nmc?oc=5","date":"2025-04-27","type":"pipeline","source":"The New York Times","summary":"Medicine Spares Cancer Patients From Grisly Surgeries and Harsh Therapies - The New York Times","headline":"Medicine Spares Cancer Patients From Grisly Surgeries and Harsh Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOMFRFTEs4cDlNMGUyazhWaWpDS1ZuMllWeGpMWFMyQkVKQmcwX2RnNGdka1VQaDJJQzhkX0lvbEo0Y0REV18tV1V2MnhDcWxXb2JQNVl1RVo3SWZVaE1FMVd6RUFTY2p5VEZZcEVZazNFcjhFVHRjcGxVUVI5QW40SnNuMEFuVm9aMnZLLUdYOE9ib3ZaRTlha1U1bmk0d3l0OUNFU3Z3bUtPYjFtMGVwQUtDMVNubThvSk1IUG1qczNXUTVsUlE?oc=5","date":"2025-02-19","type":"pipeline","source":"Pharmaceutical Technology","summary":"Amazon joins forces with Memorial Sloan Kettering for AI-powered drug discovery - Pharmaceutical Technology","headline":"Amazon joins forces with Memorial Sloan Kettering for AI-powered drug discovery","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE54UXQwOWJGUVdFOEZuVG9UTGRPVWhNN2huQVJxTFZabkxhejNHZll4VF85UWNmaUQ0MnJlMVZodVozZU94T25yUlMyZ05GdXFWRWlSM2hJdkdNN01WTFZuVkdB?oc=5","date":"2021-06-11","type":"pipeline","source":"The Cancer Letter","summary":"Roswell Park, MD Anderson, Memorial Sloan Kettering: The cancer centers that set the model for a nation - The Cancer Letter","headline":"Roswell Park, MD Anderson, Memorial Sloan Kettering: The cancer centers that set the model for a nation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOR3VxZXJ3LU9uaXdPVFU1TUZZRXpRU0dheFA4N2pJY2VDZ1dfY1RWZEZTLUFyZUhmdzlINTFTUkFvS2dqdGtzMXNMM2RMWElRb1ZLTldFaVNTVUQ4aDBTOHFqTXNXYXFrUEN0Q3A2NHRFNnFKd2dSbzI4MkVaV2NVTzdoaUg4TmFXa3RXUV9BWjVoNDN2OVAweVlmd0J3Mm50YmkwYkNR?oc=5","date":"2019-04-04","type":"pipeline","source":"ProPublica","summary":"Memorial Sloan Kettering Leaders Violated Conflict-of-Interest Rules, Report Finds - ProPublica","headline":"Memorial Sloan Kettering Leaders Violated Conflict-of-Interest Rules, Report Finds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOUHJpZDV2SXZtVVhwOTJjS3VmNFZpcEpWTWJweUJ1dVlsLWl4RkRzOVVZTjdNajVtdzZCWm1pbHJ6SnViWVNmMU9TaUVfZE9YUGxzSDQwV0xHbUdYTHJGZkVacVJfZWYwcnh0WHZ4aS0zR1dIclhsY3NTYl9lLVgxSFB0N1VmMEx5c09ZMlBsOWw3TktGODFCd1dGRjdwZDA1LUx1dEp1cXNYYV9wYklkSzQ1Tll1U1NV?oc=5","date":"2018-11-29","type":"pipeline","source":"BioPharma Dive","summary":"Memorial Sloan Kettering scandal raises questions for pharma’s biggest corporate boards - BioPharma Dive","headline":"Memorial Sloan Kettering scandal raises questions for pharma’s biggest corporate boards","sentiment":"neutral"}],"patents":[],"drugCount":45,"phaseCounts":{"phase_1":13,"phase_2":3,"marketed":16,"phase_3":13},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}